Adding tagitanlimab to treatment with gemcitabine and cisplatin improved PFS in patients with recurrent or metastatic nasopharyngeal cancer.

A training platform integrated with AI can help pathologists identify HER2-low and HER2-ultralow breast cancers with more accuracy, data suggest.

Escalating adjuvant treatment based on ctDNA positivity does not improve RFS in patients with stage III colon cancer, data suggest.

A reflex ctDNA-methylation MCED test can detect multiple cancer types in patients with obesity, a new study suggests.

Adding perioperative systemic therapy to CRS-HIPEC can improve some outcomes in patients with resectable colorectal peritoneal metastases, data suggest.

A symptom assessment intervention can reduce acute care use and costs for older adults with cancer, a study suggests.

HHS Secretary Robert F. Kennedy Jr. said this week that he may no longer allow government scientists to publish research in top medical journals.

The worse overall survival seen in transgender and gender-diverse patients may be due to treatment differences or non-breast cancer causes, researchers say.

Patritumab deruxtecan demonstrated activity against brain metastases and leptomeningeal disease in a phase 2 trial of patients with advanced cancers.

The FDA has accepted for priority review the new drug application for sevabertinib (BAY 2927088) to treat certain patients with NSCLC.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.